Abstract
International regulatory agencies have developed recommendations and guidances for bioequivalence approaches of orally inhaled drug products (OIDPs) for local action. The objective of this article is to discuss the similarities and differences among these approaches used by international regulatory authorities when applications of generic and/or subsequent entry locally acting OIDPs are evaluated. We focused on four jurisdictions that currently have published related guidances for generic and/or subsequent entry OIDPs. They are Therapeutic Goods Administration (TGA) in Australia, Health Canada (HC) in Canada, European Medicines Association (EMA) of European Union (EU), and the Food and Drug Administration (FDA) in the United States of America (USA). The comparisons of these bioequivalence (BE) recommendations are based on selection of reference products, formulation and inhaler device comparisons, and in vitro tests and in vivo studies, including pharmacokinetic (PK), pharmacodynamics (PD), and clinical studies. For the in vivo studies, the study design, choices of dose, subject inclusion/ exclusion criteria, study period, study endpoint, and equivalence criteria are elaborated in details. The bioequivalence on multiple-strength products and waiver options are also discussed.
Similar content being viewed by others
REFERENCES
Code of Federal Regulations Title 21, 320.1.
Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 2013;15(4):974–90.
EMA. Guideline on the investigation of bioequivalence. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. 2010.
EMA. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003504.pdf. 2009.
Fuglsang A. The US, and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD. J Aerosol Med Pulm Drug Deliv. 2012;25(4):243–7.
Lee SL, Adams WP, Li BV, Conner DP, Chowdhury BA, Yu LX. In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J. 2009;11(3):414–23.
Health-Canada. Guidance to establish equivalence or relative potency of safety and efficacy of a second entry short-acting beta2-agonist metered dose inhaler. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/mdi_bad-eng.pdf. 1999.
Health-Canada. Guidance for industry: pharmaceutical quality of inhalation and nasal products. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/inhalationnas-eng.pdf. 2006.
Mayers I. Introduction to the Canadian scientific advisory committee on respiratory and allergy therapies: in vivo evaluation for clinical testing in COPD and asthma therapy using generics. J Aerosol Med Pulm Drug Deliv. 2012;25:1–5.
US-FDA. Orange Book. http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.
Christopher D, Adams WP, Lee DS, Morgan B, Pan Z, Singh GJ, et al. Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols: part 2—evaluation of a method for determining equivalence. AAPS PharmSciTech. 2007;8(1):E39–48.
Health-Canada. Draft guidance document data requirements for safety and effectiveness of subsequent market entry inhaled corticosteroid products for use in the treatment of asthma. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/consultation/drug-medic/draft_inhal_ebauche_corticost-eng.pdf. 2011.
Australia. Australian guidance 19: inhalation and nasal medicines. Section 19.2.1: selecting a reference medicine. http://www.tga.gov.au/industry/pm-argpm-guidance-19-02.htm. 2013.
US-FDA. Draft guidance on fluticasone propionate; salmeterol xinafoate. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM367643.pdf. 2013.
US-FDA. Draft guidance on budesonide. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM319977.pdf. 2012.
US-FDA. Draft guidance on albuterol sulfate. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM346985.pdf. 2013.
Health-Canada. Guidance document: comparative bioavailability standards: formulations used for systemic effects. www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/gd_standards_ld_normes-eng.php. 2012.
Disclaimer
This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guest Editors: Marilyn Martinez and Lawrence Yu
Wallace Adam has been retired from the agency Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Rights and permissions
About this article
Cite this article
Lu, D., Lee, S.L., Lionberger, R.A. et al. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences. AAPS J 17, 546–557 (2015). https://doi.org/10.1208/s12248-015-9733-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-015-9733-9